First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study

• Published in: British journal of cancer Vol. 98; no. 3; pp. 558 - 563
• Main Authors: Tibaldi, C, Vasile, E, Antonuzzo, A, Di Marsico, R, Fabbri, A, Innocenti, F, Tartarelli, G, Amoroso, D, Andreuccetti, M, Dico, M Lo, Falcone, A
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 12.02.2008; Nature Publishing Group
• Subjects: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Biomedical and Life Sciences; Biomedicine; Cancer Research; Carcinoma, Non-Small-Cell Lung - drug therapy; Clinical Study; Deoxycytidine - administration & dosage; Deoxycytidine - analogs & derivatives; Docetaxel; Drug Administration Schedule; Drug Resistance; Epidemiology; Female; Humans; Lung Neoplasms - drug therapy; Male; Medical sciences; Molecular Medicine; Oncology; Pneumology; Survival Analysis; Taxoids - administration & dosage; Tumors; Tumors of the respiratory system and mediastinum; elderly patients; gemcitabine; docetaxel; advanced NSCLC; Antineoplastic agent; Gemcitabine; Lung cancer; Multicenter study; non-small cell lung carcinoma; Cancerology; Sequential; Taxane derivatives; Phase II trial; Bronchus disease; Advanced stage; Antimitotic; Pyrimidine nucleoside; Human; Lung disease; Respiratory disease; Docetaxel; Malignant tumor; First line treatment; Antimetabolic; Pyrimidine derivatives; Fluorine Organic compounds; Elderly; Cancer

This multicenter phase II study evaluated, in chemonaive patients with stage IIIB–IV NSCLC, age ⩾70 and with a performance status 0–2, the activity, efficacy and tolerability of planned sequential administration of gemcitabine 1200 mg m −2 on days 1 and 8 every 3 weeks for three courses followed by...